ResMed Inc. (RMD) Earnings

ResMed Inc.

RMD · NYSE

Jun 2026upcoming

Next quarter

Consensus is $2.90 EPS for Jun 2026 across 5 estimates, ranging $2.86 to $2.95.

RMD Mar 2026

Reported Apr 30, 2026

Beat 2.51%

EPS estimate: $2.79
EPS actual: $2.86
Revenue estimate: —
Revenue actual: —
1-day move: -4.11%

Call highlights have not been generated for this quarter.

Symbol: RMD
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home.

Key Issues

Bullish view

The Q4 preview points to strong mask and device demand and projects 13.7% EPS growth, supporting continued operating momentum.

Bearish view

A separate Zacks preview says ResMed lacks the right combination of ingredients for a likely earnings beat, raising the risk that expected growth is already reflected in estimates.

Analyst Consensus

See all

Hold

14 analysts

$223

Current

—

Low

$231

Average

—

High

Average target implies +3.76% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Becton, Dickinson and CompanyBDX · NYSE